BMRN Q4 2025 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$875M+17.0% YoY

Gross Profit

$579M66.3% margin

Operating Income

$79M9.1% margin

Net Income

-$47M-5.3% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

+12.7%

Cash Flow

Operating Cash Flow

$100M

Free Cash Flow

$59M

Stock-Based Comp.

$47M

Balance Sheet

Total Assets

$7.6B

Total Liabilities

$1.5B

Stockholders' Equity

$6.1B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$875M	$747M	+17.0%
Gross Profit	$579M	$611M	-5.2%
Operating Income	$79M	$161M	-50.8%
Net Income	-$47M	$125M	-137.3%

Revenue Segments

Product

$859M98%

Royalty And Other

$15M2%